News

InflaRx Presents Groundbreaking Advances in Dermatology Research

InflaRx Presents Groundbreaking Advances in Dermatology Research

Exciting Developments in Immuno-Dermatology

InflaRx N.V. (NASDAQ: IFRX), a pioneering biopharmaceutical company dedicated to developing anti-inflammatory therapeutics, has announced the acceptance of all its submitted abstracts for presentation at the upcoming American Academy of Dermatology (AAD) Annual Meeting. This event is set to take place from March 7 to March 11, and it will feature the promising role of Vilobelimab in treating conditions such as pyoderma gangrenosum (PG) and hidradenitis suppurativa (HS).

Highlights of the Presentation Agenda

With a strong emphasis on scientific advancement, the presentations will delve into various aspects of Vilobelimab, particularly its efficacy and innovative contributions to dermatological therapies. Dr. Camilla Chong, Chief Medical Officer at InflaRx, expressed pride in the acceptance of these abstracts, highlighting the rigorous research behind the clinical development of Vilobelimab. Notably, for the first time, findings on the reduction of draining tunnels (dTs) in HS patients will be unveiled.

Abstracts to be Presented

Oral Poster Presentation

Vilobelimab Safety in Pyoderma Gangrenosum Patients: A Phase 2a Explorative Dose-Finding Study
Authors: Afsaneh Alavi, Benjamin H. Kaffenberger, Hoda Tawfik, Camilla Chong, Bruce P. Burnett
Date/Time: March 8, 2025, 10:15 AM - 10:20 AM

ePoster Highlights

Several important ePosters will be showcased, including:

  • Pharmacokinetic/Pharmacodynamic Analysis of Vilobelimab and Complement C3 and C5a in a Randomized, Controlled Multidose Phase 2a Study in Pyoderma Gangrenosum.
  • Reduction in Draining Tunnels in Hidradenitis Suppurativa Patients Treated with Vilobelimab.
  • Vilobelimab Post-hoc Efficacy in Hidradenitis Suppurativa using the Modified HiSCR with Data from the Phase 2b SHINE Study.

The Mechanism Behind Vilobelimab

Vilobelimab stands out as a first-in-class monoclonal antibody specifically targeting human complement factor C5a. This antibody demonstrates remarkable selectivity, making it a valuable asset in controlling inflammatory responses without disrupting critical defense mechanisms of the innate immune system. The unique property of not altering the membrane attack complex allows Vilobelimab to manage inflammatory damage effectively.

Developing Vilobelimab for Critical Conditions

The development of Vilobelimab extends into various severe inflammatory diseases, with current focus on a Phase 3 trial aimed at addressing pyoderma gangrenosum. The approval status includes orphan drug designation from both the FDA and EMA, reinforcing the drug's significance in treating life-threatening conditions.

Regulatory Approvals and Ongoing Research

In addition to its ongoing trials, GOHIBIC, the brand name for Vilobelimab in the U.S., has been granted Emergency Use Authorization by the FDA for COVID-19 treatment. While this is limited to specific qualifying conditions, the drug’s versatility demonstrates its potential across different severe health issues.

Moreover, in the EU, GOHIBIC has received marketing authorization under exceptional circumstances for treating acute respiratory distress syndrome (ARDS), showcasing the breadth of its application beyond dermatology.

The Corporate Vision of InflaRx

Founded in 2007, InflaRx N.V. is committed to spearheading the development of innovative anti-inflammatory therapeutics by harnessing proprietary technologies. Their lead candidate, Vilobelimab, continues to show promise across various indications, signaling a brighter future for treatment options in the dermatology landscape.

Frequently Asked Questions

What is Vilobelimab used for?

Vilobelimab is primarily developed to address inflammatory conditions such as pyoderma gangrenosum and hidradenitis suppurativa.

When will InflaRx present their research?

The research findings will be presented at the AAD Annual Meeting from March 7 to March 11, 2025.

What did Dr. Camilla Chong say about the presentations?

Dr. Chong expressed pride in the acceptance of the abstracts, emphasizing the extensive clinical development work behind Vilobelimab.

Is Vilobelimab approved for COVID-19 treatment?

Yes, GOHIBIC (Vilobelimab) is authorized for emergency use by the FDA for treating COVID-19 in certain hospitalized adults.

What regulatory designations has Vilobelimab received?

Vilobelimab has received orphan drug designation and fast-track designation from the FDA and EMA for various treatments.

About The Author

About Investors Hangout

Investors Hangout is a leading online stock forum for financial discussion and learning, offering a wide range of free tools and resources. It draws in traders of all levels, who exchange market knowledge, investigate trading tactics, and keep an eye on industry developments in real time. Featuring financial articles, stock message boards, quotes, charts, company profiles, and live news updates. Through cooperative learning and a wealth of informational resources, it helps users from novices creating their first portfolios to experts honing their techniques. Join Investors Hangout today: https://investorshangout.com/

The content of this article is based on factual, publicly available information and does not represent legal, financial, or investment advice. Investors Hangout does not offer financial advice, and the author is not a licensed financial advisor. Consult a qualified advisor before making any financial or investment decisions based on this article. This article should not be considered advice to purchase, sell, or hold any securities or other investments. If any of the material provided here is inaccurate, please contact us for corrections.

Top 10 Most Recent News Articles

Vail Resorts Bets on Music to Deepen Epic Pass Demand

Updated Category News Views 119

A bass drop at 11,000 feet is not merely a party trick when you run 42 mountain resorts. Vail Resorts is putting live music, après programming and destination events squarely beside skiing and riding for winter 2026-27, and the business logic is pretty plain: give people another reason to buy early, stay longer and return with friends. For investors watching MTN, this is...

Continue Reading
NYSE Message Record Puts Market Plumbing Into Focus

Updated Category News Views 120

A trillion messages is not a cute little exchange statistic; it is the sort of number that tells you whether the market’s pipes can keep working when everybody starts shouting at once. NYSE says it handled a record 1.166 trillion messages in one day on November 5, roughly 4% above the prior high set amid April 2025 volatility. Better yet, according to the exchange,...

Continue Reading
LGT Middle East Win Highlights Patient Private Banking

Updated Category News Views 166

A trophy in Dubai is not a balance sheet, but it can be a useful calling card when the clientele measures relationships in decades rather than quarters. LGT Middle East was named Best Pure Play Private Bank at the WealthBriefing MENA Awards 2026, at a ceremony held in Dubai on November 18. For a family-owned wealth manager working with Middle Eastern families, that sort...

Continue Reading
Holland America Puts 2028 Alaska Demand on Display

Updated Category News Views 123

Alaska’s interior is where a cruise brochure either earns its keep or gets exposed. Holland America Line is opening bookings for 2028 Alaska Cruisetours nearly two years ahead, tying a coast-and-land product to the reimagined Oosterdam’s Alaska debut. That is not merely another itinerary release. It is a fairly deliberate attempt to sell a bigger, longer and...

Continue Reading
New York's $1.2M Prison Abuse Deal Raises State Stakes

Updated Category News Views 30

One courtroom result can expose a whole warehouse of institutional neglect, and this one lands with a grim thud. New York has agreed to pay $1.2 million to resolve a claim involving sexual assault by a former corrections officer at Bayview Correctional Facility in Manhattan. The settlement came after a two-week Adult Survivors Act bellwether trial concluded on November 17...

Continue Reading
Africa’s Digital Leap Still Has a 64% Usage Problem

Updated Category News Views 100

A continent can be blanketed in signal and still feel digitally stranded. That is the stubborn fact sitting inside the GSMA Digital Africa Index 2026: mobile broadband reaches 92% of Africa’s population, while only 28% use mobile internet on their own devices. The 64% usage gap is not a rounding error or a tidy policy footnote. It is the whole unfinished job. From an...

Continue Reading
SciBase Sets Its 2027 AGM Nominating Committee Early

Updated Category News Views 94

Four names on a committee roster rarely make anyone pound the table, and they should not. Still, SciBase Holding has put an important bit of corporate housekeeping in place for its 2027 Annual General Meeting: the nominating committee that will handle shareholder-facing governance work ahead of the May 20 meeting in Stockholm. For a small listed medical-technology...

Continue Reading
Ajman Forum Puts Trust at the Center of Crisis Media

Updated Category News Views 82

Rumours do not wait politely for a communications team to finish its meeting. That plain reality sat underneath Abdulla bin Mohammed bin Butti Al Hamed's keynote at Ajman Media Forum 2026, and it is a tougher point than the usual talk about reach, engagement, or flashy new technology. In a crisis, an information vacuum gets filled fast, usually by somebody with no...

Continue Reading
RUDSAK Tests Premium Demand From Toronto to New York

Updated Category News Views 145

A coat rack on Bloor Street can tell a harsher story than a glossy expansion announcement. RUDSAK has opened a Toronto flagship at 55 Bloor Street West in the Manulife Centre and is preparing a boutique at American Dream outside New York City. This is a real step up in retail ambition for the Montréal luxury outerwear house, founded in 1994, and it deserves more than the...

Continue Reading
Shenzhen Three-Way Summit Puts Stability to the Test

Updated Category News Views 153

Three nuclear powers sharing a room in Shenzhen is the sort of headline that makes every risk desk sit upright, even when the paperwork remains thin. CGTN reports that Chinese President Xi Jinping, Russian President Vladimir Putin and U.S. President Donald Trump met on November 19, 2026, in an unprecedented trilateral summit and issued a Declaration toward Peace. That is...

Continue Reading

Top 5 Most Recently Viewed Articles

bioAffinity Technologies Launches $2.66 Million Funding Initiative

Updated Category News Views 207

Exciting Funding Development Announced by bioAffinity Technologies bioAffinity Technologies, Inc. (Nasdaq: BIAF; BIAFW), a pioneering company in the field of biotechnology, has announced an exciting funding development that is set to enhance its capability in the noninvasive detection of early-stage cancer. The company has entered into a securities purchase agreement with...

Continue Reading
Wendy's Expands Its Franchise Opportunities in Tijuana

Updated Category News Views 132

Wendy's Expands Its Franchise Opportunities in Tijuana The Wendy's Company is seeking passionate and experienced franchise partners as it intensifies its expansion strategy in Tijuana and the larger Baja California region. With the aim to develop new restaurant locations, Wendy's recognizes the potential to thrive in this vibrant market. The company has planned a...

Continue Reading
Insights into Upcoming Earnings for Vail Resorts

Updated Category News Views 215

Anticipating Vail Resorts' Earnings Report Vail Resorts (NYSE: MTN) is gearing up to release its latest quarterly earnings report, and the anticipation among investors is palpable. This upcoming announcement will shed light on the company's financial performance, and many are eagerly awaiting the results. Analyst Earnings Estimates Forecasts suggest that Vail Resorts...

Continue Reading
Creatv Bio's Innovative Blood Test for Colorectal Cancer Trials

Updated Category News Views 115

Revolutionary LifeTracDx® Blood Test in Colorectal Cancer Trials Creatv Bio, a division of Creatv MicroTech, Inc., is taking significant strides in the realm of cancer diagnostics. The introduction of their LifeTracDx® blood test in collaboration with CytoDyn Therapeutics Corporation marks a promising development in assessing patient responses to innovative treatments....

Continue Reading
Freedom Mortgage Celebrates 9 Years of Excellence with STAR Award

Updated Category News Views 212

Freedom Mortgage Earns Prestigious Recognition Again Freedom Mortgage has once again made headlines by receiving the Fannie Mae Servicer Total Achievement and Rewards™ (STAR™) Performer Award for an impressive ninth consecutive year. This accolade highlights Freedom Mortgage as a leading performer in the mortgage servicing industry, particularly for its remarkable...

Continue Reading